Načítá se...
Checkpoint inhibitors in ovarian cancer: A review of preclinical data
Ovarian cancer is the deadliest gynecologic malignancy, and relapse after initial treatment is frequently fatal. Although ovarian cancer typically has an immunosuppressive tumor microenvironment, a strong intratumoral T cell presence is associated with an improved response to chemotherapy and better...
Uloženo v:
| Vydáno v: | Gynecol Oncol Rep |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elsevier
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6609798/ https://ncbi.nlm.nih.gov/pubmed/31312712 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.gore.2019.06.003 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|